TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template

TG THERAPEUTICS INC (NASDAQ:TGTX) has been identified as a high-growth momentum stock that aligns with Mark Minervini’s Trend Template criteria. The company, focused on novel treatments for B-cell malignancies and autoimmune diseases, shows strong technical and fundamental characteristics that may appeal to growth-oriented investors.

Why TGTX Fits the Minervini Trend Template

Minervini’s strategy emphasizes stocks in strong uptrends with clear technical strength. TGTX meets several key criteria:

• Price Above Key Moving Averages:

  • Current price ($37.09) is above the 50-day ($36.59), 150-day ($35.12), and 200-day ($32.98) moving averages.
  • The 50-day MA is above both the 150-day and 200-day MAs, confirming bullish alignment.

• Upward-Trending Moving Averages:

  • The 200-day MA is rising, reinforcing long-term strength.

• Strong Relative Strength:

  • TGTX outperforms 89% of all stocks, indicating market leadership.

• Price Near 52-Week High:

  • The stock is within 25% of its 52-week high ($46.48) and well above its 52-week low ($16.65).

High-Growth Fundamentals

Beyond technicals, TGTX exhibits strong growth metrics:

• Earnings Growth:

  • EPS grew 1,300% YoY in the last fiscal year.
  • Recent quarterly EPS growth: 142.9% (Q2Q) and 250% (Q-1).

• Revenue Expansion:

  • Revenue surged 90.4% in the latest quarter and 40.8% YoY.
  • The company has beaten revenue estimates in all of the last four quarters.

• Profitability Improvements:

  • Profit margins expanded to 4.19% (latest quarter), up from negative figures in prior periods.

Technical Setup & Risk Considerations

The stock is consolidating near resistance at $37.09–$37.27, with support at $36.47–$36.69. A breakout above resistance could signal further upside, while a drop below support may indicate a pullback.

Our High Growth Momentum + Trend Template screener lists more stocks with similar growth and technical strength.

For a deeper technical analysis, review the full TGTX technical report.

Disclaimer

This is not investing advice. Always conduct your own research and consider risk management before making investment decisions.